Can a noncancerous (benign) wound be CD34 (cluster of differentiation 34) negative?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can a Noncancerous Wound Be CD34 Negative?

Yes, noncancerous wounds are characteristically CD34 negative within the scar tissue itself, though CD34-positive cells actually increase in the surrounding pericicatricial tissue during healing. 1

CD34 Expression in Normal Wound Healing

In normal skin and wound healing, CD34 demonstrates a predictable pattern:

  • Normal dermis contains CD34-positive dendritic stromal cells distributed throughout, along with CD34 expression in endothelial cells, perifollicular cells, and eccrine glands 1

  • Mature scar tissue is completely devoid of CD34-positive stromal cells - the cicatricial tissue itself shows total absence of CD34 staining 1

  • Pericicatricial tissue (dermis adjacent to scars) shows significantly increased CD34-positive cells compared to normal skin (41.5 cells/mm² versus 24.5 cells/mm², p<0.001), suggesting these cells play a role in scar remodeling 1

Critical Diagnostic Pitfall

The augmented CD34 labeling around healing wounds and scars should not be misinterpreted as evidence of tumor persistence or recurrence, particularly when evaluating margins after excision of CD34-positive malignancies like dermatofibrosarcoma protuberans (DFSP) 1

This is especially important because:

  • DFSP is typically CD34-positive in 92% of cases with diffuse staining 2
  • CD34 immunohistochemistry may be used to aid margin assessment during DFSP excision 3, 2
  • The physiologic increase in pericicatricial CD34-positive cells could be confused with residual tumor if this normal healing pattern is not recognized 1

CD34 in Other Benign Lesions

Some benign lesions can show variable CD34 expression:

  • Cellular benign fibrous histiocytoma shows CD34 positivity in 6% of cases, though this should not deter from correct diagnosis based on morphologic features 4
  • Benign breast lesions typically retain CD34 positivity in stromal myofibroblasts, unlike malignant tumors which lose CD34 expression 5

Clinical Application

When evaluating a wound or scar:

  • Absence of CD34 in scar tissue is normal and expected 1
  • Increased CD34 staining around the scar periphery is a physiologic healing response, not pathologic 1
  • If concerned about tumor recurrence, correlate CD34 staining pattern with morphology - tumor cells show different architectural patterns than the dendritic stromal cells of normal healing 3, 2

References

Guideline

Immunohistochemistry Profile in Malignant Dermatofibrosarcoma Protuberans

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.